Back to search results

Ribupatide for Obesity Without Diabetes

This study is testing a new medication called Ribupatide for people living with obesity who do not have diabetes. Researchers want to see if Ribupatide, given as a shot under the skin (subcutaneous injection) once a week, helps people lose more weight than Semaglutide (another medication for weight loss) or a placebo (an inactive shot). You could be eligible if you are 18 or older, have a Body Mass Index (BMI) of 35 or higher, and have tried to lose weight with diet and exercise in the last 6 months without success. You cannot have diabetes or have started medications that cause significant weight changes recently. The main goal is to measure the percentage of body weight lost after 76 weeks.

Study design
This is an interventional study planning to enroll 1200 participants. It compares Ribupatide to Semaglutide and a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your body weight will be measured at the beginning of the study and again at Week 76.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07284979

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Recruiting
PHASE3Ages 18+InterventionalTreatment
Kailera
~1,200 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:RibupatideSemaglutidePlacebo

At a glance

Recruiting sites
53 of 53 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent Change From Baseline in Body Weight at Week 76
Measured over Baseline, Week 76

Conditions

Obesity

Explore related trials

Obesity

Where it's being run

53 sites across 38 states
Queensland3
Bulgaria3
Arizona2
California2
Connecticut2
Illinois2
North Carolina2
South Carolina2

Study leadership

  • Medical Director · STUDY_DIRECTOR · Kailera Therapeutics, Inc.

Who to contact

Kailera Therapeutics, Inc.
[email protected]
781-317-0291
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

BMI ≥35 kilograms per square meter (kg/m\^2).
History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months.

Exclusion

Current diagnosis or history of diabetes mellitus.
Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, mood stabilizers, and phentermine.
Unstable weight defined as self-reported change in body weight exceeding 5% within the 3 months prior to Screening.
Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.
Uncontrolled hypertension or unstable cardiovascular disease.
History of chronic or acute pancreatitis.
Known clinically significant gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility.
History of suicide attempt.
History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder.
Received treatment with semaglutide, tirzepatide, glucagon-like peptide-1 receptor (GLP-1R) agonist, GLP-1/glucose-dependent insulinotropic polypeptide (GIP), or glucagon receptor agonist within 3 months prior to Screening.

What this trial measures

  • Percent Change From Baseline in Body Weight at Week 76Baseline, Week 76